Indirect Hemagglutination Test for Detection of Antibodies to Cytomegalovirus

Bernstein, Michael T.; Stewart, John A.

doi:10.1128/aem.21.1.84-89.1971

Cited by 50 publications

(18 citation statements)

References 3 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It follows, therefore, that both procedures could be used with confidence for screening sera for these applications. It should be emphasized that the calculations of predictive value performed in this study should be applicable to general laboratory practice, since the prevalence of CMV antibody in our sample (i.e., 44.8%) closely approximates that reported for the general population (i.e., 40 to 70%) (2,3,6).…”

Section: Methodssupporting

confidence: 70%

Detection of cytomegalovirus antibody with two commercially available assays, an indirect hemagglutination test and an enzyme immunosorbent assay

Cheeseman¹,

Doern²,

Ferriani³

et al. 1984

J Clin Microbiol

View full text Add to dashboard Cite

By the use of two reference procedures, an indirect hemagglutination assay and a complement fixation test, the presence or absence of cytomegalovirus (CMV) antibody was determined for 221 human sera. Ninety-nine sera (44.8%) were found to contain CMV antibody. The remaining 122 sera (55.2%) lacked detectable CMV antibody. These same sera were then analyzed by two recently introduced, commercially available CMV antibody assays, an indirect hemagglutination test (IHA-c; Cetus Corp., Emeryville, Calif.) and an enzymelinked immunosorbent assay (ELISA; M. A. Bioproducts, Walkersville, Md.). With the results of the reference procedures as true evidence of the presence or absence of CMV antibody, the sensitivity of the IHA-c was found to be 100%; the specificity was 98.4%. The sensitivity of the ELISA was also 100%; the specificity was 96.7%. The overall accuracies of these procedures were 99.1 and 98.2%, respectively. Time and motion studies revealed the IHA-c procedure to be faster and technically less demanding than the ELISA procedure.

show abstract

Section: Methodssupporting

confidence: 70%

Detection of cytomegalovirus antibody with two commercially available assays, an indirect hemagglutination test and an enzyme immunosorbent assay

Cheeseman¹,

Doern²,

Ferriani³

et al. 1984

J Clin Microbiol

View full text Add to dashboard Cite

show abstract

“…All plasma specimens were stored at -20 C and later tested simultaneously in duplicate under code with the same CMV antigen preparation. The method of Bernstein and Stewart (1) with minor modifications (personal communication, John A. Stewart) was used for the preparation of antigen (AD 169 strain) and for the measurement of indirect hemagglutination (IHA) antibody. Complement-fixing (CF) antibody was measured by the Laboratory Branch microtiter CF technique (2).…”

Section: Methodsmentioning

confidence: 99%

Cytomegalovirus infection in a volunteer blood donor population

Kane¹,

Rousseau²,

Noble³

et al. 1975

Infect Immun

View full text Add to dashboard Cite

Among 223 volunteer blood donors who were studied for evidence of cytomegalovirus (CMV) infection, 58 percent had complement-fixing antibody and 59 percent had indirect hemagglutinating antibody to CMV. No virus was isolated from any donor's washed leukocytes or leukocyte-rich plasma in fibroblast monolayer culture. In seven asymptomatic donors (3 percent), CMV was recovered from urine cultures obtained at the time of blood donation. However, at the time of reexamination, viruria was no longer present and serum antibody titers had not changed. In the three patients studied who received blood from three of the cytomegaloviruric donors, serological evidence of CMV infection developed (fourfold or greater indirect hemagglutinating antibody rise), and one recipient also developed cytomegaloviruria; no illnesses was associated with these infections. Further study is needed to establish that the detection of viruria in donors may identify potentially infective blood.

show abstract

“…Rubella Viruses Antibodies to CMV were measured using complement fixation (CF) and an indirect hemagglutination test (IHA). 22 Antibodies to varicella-zoster (VZ) were measured using CF and an immune adherence hemagglutination-" while those to rubella were measured by single-radial hemolysis and hemagglutination-Inhibition'" and those to herpes hominis (HH) by CF and IHA methods." RESULTS We found that many of the pregnant women showed reactivation of EBV as evidenced by excretion of virus in throat and by elevated IgG anti-VCA and anti-EA.…”

Section: Antibodies To Cytomegalovirus Varicella-zoster Andmentioning

confidence: 99%

Epstein‐Barr Virus in Normal Pregnant Women*

Saito

Greally

Gilfillan

et al. 1982

American Journal of Reproductive Immunology

View full text Add to dashboard Cite

Acquired immune suppression accompanying normal pregnancy may be associated with reactivation of Epstein-Barr virus (EBV). Pregnant women with reactivated EBV having anti-EA antibodies show high titers of antiviral capsid antigen (VCA) geometric mean titers (GMT) of 522 versus 170 in those lacking anti-early antigen (EA). Among twenty-seven seropositive women at parturition, 17 (63%) had generated antibody to EA, and all 27 (100%) demonstrated significant increases in antibody to VCA (p less than 0.01). In contrast, antibody titers to cytomegalovirus, herpes hominis, varicella-zoster, and rubella viruses in the pregnant women were comparable to those found in nonpregnant controls. (Am J Reprod Immunol. 1982; 2:217-221.)

show abstract

Indirect Hemagglutination Test for Detection of Antibodies to Cytomegalovirus

Cited by 50 publications

References 3 publications

Detection of cytomegalovirus antibody with two commercially available assays, an indirect hemagglutination test and an enzyme immunosorbent assay

Detection of cytomegalovirus antibody with two commercially available assays, an indirect hemagglutination test and an enzyme immunosorbent assay

Cytomegalovirus infection in a volunteer blood donor population

Epstein‐Barr Virus in Normal Pregnant Women*

Contact Info

Product

Resources

About